
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **PLN (Phospholamban):** Involved in cardiac muscle contraction regulation, but also expressed in smooth muscle cells.<br>- **RGS5 (Regulator of G-protein Signaling 5):** Known to be involved in vascular smooth muscle cell function and pericyte biology.<br>- **GJA4 (Gap Junction Protein Alpha 4):** Encodes connexin 37, involved in cell communication, particularly in endothelial cells.<br>- **MT1A (Metallothionein 1A):** Involved in metal ion binding and detoxification.<br>- **MYH11 (Myosin Heavy Chain 11):** A smooth muscle myosin, indicating smooth muscle cell function.<br>- **IGFBP7 (Insulin-like Growth Factor Binding Protein 7):** Involved in cell adhesion and growth regulation.<br>- **ACTA2 (Alpha Smooth Muscle Actin):** A classic marker for smooth muscle cells and myofibroblasts.<br>- **PDGFRB (Platelet-Derived Growth Factor Receptor Beta):** Expressed in pericytes and vascular smooth muscle cells, involved in cell proliferation and migration.<br>- **COL4A1 (Collagen Type IV Alpha 1 Chain):** A component of the basement membrane, involved in structural integrity.<br>- **EPAS1 (Endothelial PAS Domain Protein 1):** Also known as HIF-2Œ±, involved in response to hypoxia, often expressed in endothelial cells.<br><br>### Step 2: List the Key Cell Type Markers<br>- **MYH11, ACTA2, TAGLN (Transgelin), CALD1 (Caldesmon 1), MYL9 (Myosin Light Chain 9):** These are all markers associated with smooth muscle cells.<br>- **PDGFRB, RGS5, MCAM (Melanoma Cell Adhesion Molecule):** Markers associated with pericytes and vascular smooth muscle cells.<br>- **GJA4, EPAS1:** Markers associated with endothelial cells.<br>- **COL4A1, COL4A2, COL18A1:** Collagen markers, often associated with extracellular matrix and basement membrane, relevant to endothelial and smooth muscle cells.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on scRNA-seq datasets, the markers listed are predominantly associated with vascular smooth muscle cells and pericytes. The presence of ACTA2, MYH11, and TAGLN strongly suggests a smooth muscle lineage, while PDGFRB and RGS5 are indicative of pericytes.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of these markers, the most likely general cell type is **vascular smooth muscle cells**. The presence of ACTA2, MYH11, and other smooth muscle markers supports this conclusion.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Vascular Smooth Muscle Cells:** The high expression of ACTA2, MYH11, and TAGLN strongly supports this subtype.<br>2. **Pericytes:** The expression of PDGFRB and RGS5 suggests a pericyte identity, which is closely related to vascular smooth muscle cells.<br>3. **Endothelial Cells:** The presence of GJA4 and EPAS1 suggests a possible endothelial cell identity, although less likely given the dominance of smooth muscle markers.<br><br>The most likely subtype based on the markers is **vascular smooth muscle cells**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset indicates that the cell cluster is most likely composed of vascular smooth muscle cells. This conclusion is supported by the high expression of smooth muscle-specific markers such as ACTA2, MYH11, and TAGLN. Pericytes and endothelial cells are considered as less likely subtypes due to the presence of PDGFRB, RGS5, and GJA4, but the overall marker profile strongly favors a smooth muscle cell identity.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. The analysis correctly identifies vascular smooth muscle cells as the most probable cell type based on the high expression of smooth muscle-specific markers such as ACTA2, MYH11, and TAGLN. The presence of markers like PDGFRB and RGS5 also supports the potential presence of pericytes, which are closely related to vascular smooth muscle cells. Additionally, the presence of GJA4 and EPAS1 suggests a possible, though less likely, endothelial cell identity.<br><br>The annotation process has appropriately considered the possibility of mixed cell types, acknowledging the presence of markers for pericytes and endothelial cells, but ultimately concluding that the marker profile strongly favors a smooth muscle cell identity. The analysis is thorough and aligns with known databases and literature, supporting the final annotation of vascular smooth muscle cells.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">vascular smooth muscle cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>pericytes</li><li>endothelial cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a thorough and methodical approach to identifying the cell types present in the single-cell dataset derived from human breast cancer tissue. The analysis correctly identifies vascular smooth muscle cells as the primary cell type, supported by the presence of key markers such as ACTA2, MYH11, and TAGLN. These markers are well-known indicators of smooth muscle cell identity, and their prominence in the list justifies the conclusion.<br><br>The annotation also considers the presence of pericytes and endothelial cells, supported by markers like PDGFRB, RGS5, GJA4, and EPAS1. This indicates a balanced consideration of multiple markers, rather than an over-focus on a single marker, which is a strength of the analysis. The inclusion of these additional cell types suggests an awareness of the potential complexity and heterogeneity within the dataset, which is crucial for capturing the general picture of the cell populations.<br><br>The analysis effectively uses known databases and literature to cross-reference the markers, adding credibility to the conclusions drawn. The step-by-step approach ensures that each marker's role and relevance are considered, leading to a comprehensive view of the cell types present.<br><br>However, there are a few areas where the analysis could be improved. While the annotation considers the rank of the markers, it could more explicitly discuss the significance of the order in which markers appear, as markers listed earlier may carry more weight in determining cell identity. Additionally, while the analysis acknowledges the possibility of mixed cell types, it could further explore this aspect, given the complexity of tumor microenvironments.<br><br>Overall, the annotation is scientifically accurate, well-balanced, and provides a comprehensive view of the cell types present, with minor areas for improvement in discussing marker rank and potential mixed cell types.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    